Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/22221751.2020.1780951 http://scihub22266oqcxt.onion/10.1080/22221751.2020.1780951 32529906!7473126!32529906     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Emerg+Microbes+Infect 2020 ; 9 (1): 1497-1505 Nephropedia Template TP {{tp|p=32529906|t=2020. Serological differentiation between COVID-19 and SARS infections |pdf=|usr=}}{{32529906}} gab.com Text Serological differentiation between COVID-19 and SARS infections JO: Emerg Microbes Infect http://www.kidney.de/pget.php?&tw=1&pmid=32529906 #FOAvip In response to the coronavirus disease 2019 (COVID-19) outbreak, caused by SARS-CoV-2, multiple diagnostic tests are required for acute disease diagnosis, contact tracing, monitoring asymptomatic infection rates and assessing herd immunity. While PCR remains the frontline test of choice in the acute diagnostic setting, serological tests are urgently needed. Unlike PCR tests which are highly specific, cross-reactivity is a major challenge for COVID-19 antibody tests considering there are six other coronaviruses known to infect humans. SARS-CoV is genetically related to SARS-CoV-2 sharing approximately 80% sequence identity and both belong to the species SARS related coronavirus in the genus Betacoronavirus of family Coronaviridae. We developed and compared the performance of four different serological tests to comprehensively assess the cross-reactivity between COVID-19 and SARS patient sera. There is significant cross-reactivity when N protein of either virus is used. The S1 or RBD regions from the spike (S) protein offers better specificity. Amongst the different platforms, capture ELISA performed best. We found that SARS survivors all have significant levels of antibodies remaining in their blood 17 years after infection. Anti-N antibodies waned more than anti-RBD antibodies, and the latter is known to play a more important role in providing protective immunity. Twit Text FOAVip Serological differentiation between COVID-19 and SARS infections ????Emerg Microbes Infect http://www.kidney.de/pget.php?&tw=1&pmid=32529906 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32529906 #FOAvip English Wikipedia <ref>{{Cite pmid|32529906}}</ref> Serological differentiation between COVID-19 and SARS infections #MMPMID32529906 Chia WN; Tan CW; Foo R; Kang AEZ; Peng Y; Sivalingam V; Tiu C; Ong XM; Zhu F; Young BE; Chen MI; Tan YJ; Lye DC; Anderson DE; Wang LF Emerg Microbes Infect 2020[Dec]; 9 (1): 1497-1505 PMID32529906show ga In response to the coronavirus disease 2019 (COVID-19) outbreak, caused by SARS-CoV-2, multiple diagnostic tests are required for acute disease diagnosis, contact tracing, monitoring asymptomatic infection rates and assessing herd immunity. While PCR remains the frontline test of choice in the acute diagnostic setting, serological tests are urgently needed. Unlike PCR tests which are highly specific, cross-reactivity is a major challenge for COVID-19 antibody tests considering there are six other coronaviruses known to infect humans. SARS-CoV is genetically related to SARS-CoV-2 sharing approximately 80% sequence identity and both belong to the species SARS related coronavirus in the genus Betacoronavirus of family Coronaviridae. We developed and compared the performance of four different serological tests to comprehensively assess the cross-reactivity between COVID-19 and SARS patient sera. There is significant cross-reactivity when N protein of either virus is used. The S1 or RBD regions from the spike (S) protein offers better specificity. Amongst the different platforms, capture ELISA performed best. We found that SARS survivors all have significant levels of antibodies remaining in their blood 17 years after infection. Anti-N antibodies waned more than anti-RBD antibodies, and the latter is known to play a more important role in providing protective immunity. |Antibodies, Viral/blood/*immunology[MESH] |Betacoronavirus/*immunology/isolation & purification[MESH] |COVID-19[MESH] |COVID-19 Testing[MESH] |Clinical Laboratory Techniques/*methods[MESH] |Coronavirus Infections/*diagnosis[MESH] |Coronavirus Nucleocapsid Proteins[MESH] |Cross Reactions[MESH] |Diagnosis, Differential[MESH] |Enzyme-Linked Immunosorbent Assay/methods[MESH] |HEK293 Cells[MESH] |Humans[MESH] |Immunoprecipitation[MESH] |Nucleocapsid Proteins/immunology[MESH] |Pandemics[MESH] |Phosphoproteins[MESH] |Pneumonia, Viral/*diagnosis[MESH] |Protein Domains/immunology[MESH] |SARS-CoV-2[MESH] |Serologic Tests/*methods[MESH] |Severe Acute Respiratory Syndrome/*diagnosis[MESH] |Severe acute respiratory syndrome-related coronavirus/*immunology/isolation & purification[MESH]Serological differentiation between COVID-19 and SARS infections (epmc).pdf DeepDyve Pubget Overpricing